Relief Reports that its U.S. Collaboration Partner Announces Data Safety Monitoring Board (DSMB) Update on the U.S. National Institutes of Health (NIH) Study of aviptadil in Critical COVID-19Accesswire • 05/26/22
NRx Pharmaceuticals Announces Data Safety Monitoring Board (DSMB) Update on U.S. National Institutes of Health (NIH) Study of ZYESAMI® (aviptadil) in Critical COVID-19PRNewsWire • 05/26/22
NRx Pharmaceuticals Leaders to Present at the H.C. Wainwright & Co. Global Investment ConferencePRNewsWire • 05/19/22
NRx Pharmaceuticals, Inc. (NRXP) CEO Robert Besthof on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/16/22
NRx Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial ResultsPRNewsWire • 05/16/22
NRx Pharmaceuticals Announces Enrollment of First Patient in Phase II Study of Bipolar Depression with Sub-Acute SuicidalityPRNewsWire • 05/12/22
NRX PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of NRx Pharmaceuticals, Inc. - NRXPBusiness Wire • 05/05/22
Relief Reports that its U.S. Collaboration Partner has Filed a New Breakthrough Therapy Designation Request for AviptadilAccesswire • 04/22/22
NRx Pharmaceuticals Again Requests For FDA Breakthrough Therapy Status For COVID-19 TherapyBenzinga • 04/21/22
NRx Pharmaceuticals Files New Breakthrough Therapy Designation Request for ZYESAMI® (aviptadil) in Subgroup of Patients with Critical COVID-19 with Respiratory Failure that were also treated with Remdesivir and continued to progressPRNewsWire • 04/21/22
NRx Pharmaceuticals' Interim CEO and other Leaders to Present at 21st Annual Needham Virtual Healthcare ConferencePRNewsWire • 04/08/22
NRx Pharmaceuticals, Inc. (NRXP) CEO Robert Besthof on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/31/22
NRx Pharmaceuticals Provides Business Update and Reports Full Year 2021 Financial ResultsPRNewsWire • 03/31/22
NRXP Monday Deadline: ROSEN, A Top Ranked Law Firm, Encourages NRx Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Monday Deadline in Securities Class Action - NRXP, NRXPWNewsfile Corp • 03/19/22
Deadline Monday Reminder: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 03/18/22
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against NRx Pharmaceuticals, Inc. (NRXP)Business Wire • 03/18/22
NRx Pharmaceuticals, Inc. Appoints Ira Strassberg as Chief Financial Officer and TreasurerPRNewsWire • 03/18/22
MONDAY DEADLINE: NRx Pharmaceuticals, Inc. Investors with Significant Losses Have Opportunity to Lead Class Action Lawsuit - NRXP; NRXPWPRNewsWire • 03/18/22
Deadline Monday Notice: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 03/17/22
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in NRx Pharmaceuticals, Inc, of Class Action Lawsuit and Upcoming Deadline - NRXP; NRXPWPRNewsWire • 03/17/22
